Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A bitter melon natural compound ameliorates the myotonic dystrophy type 1 skeletal muscle phenotype in a sex-specific manner.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics - 1 Sept 2026

Atieh Shatha A, Fahmi Chimène, Liu Jia, Tang Chunping, Ye Yang, Ravel-Chapuis Aymeric, Jasmin Bernard J

Abstract excerpt

Myotonic Dystrophy Type 1 (DM1) is a multisystemic neuromuscular disease characterized by severe skeletal muscle dysfunction. The etiology of DM1 is primarily driven by RNA toxicity resulting from a gain-of-function mutation in DMPK mRNAs. Beyond this hallmark, DM1 is also characterized by the repression of the AMP-activated protein kinase (AMPK) pathway. Previous work has shown that targeting AMPK represents a...

Read the complete abstract on PubMed

Topics

Animals
Myotonic Dystrophy
Male
Female
Momordica charantia
Mice

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Muscle, Skeletal

Phenotype

AMP-Activated Protein Kinases

Sex Characteristics

Plant Extracts

Source

Open in PubMed Open full text

Identifiers

PMID: 42546518
DOI: 10.1016/j.neurot.2026.e00978
PMCID: PMC13448424

Genes

CELF1
DMPK
MBNL1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 25 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A bitter melon natural compound ameliorates the myotonic dystrophy type 1 skeletal muscle phenotype in a sex-specific manner.PMID 42546518Read ↗

Combinatorial treatment with exercise and AICAR potentiates the rescue of myotonic dystrophy type 1 mouse muscles in a sex-specific mannerSemantic proximity Read ↗

Acute, next‐generation AMPK activation initiates a disease‐resistant gene expression program in dystrophic skeletal muscleSemantic proximity Read ↗

Direct AMPK Activation Confers Mutation-Independent Therapeutic Benefit in Duchenne Muscular Dystrophy.Semantic proximity Read ↗

Natural Compound Boldine Lessens Myotonic Dystrophy Type 1 Phenotypes in DM1 Drosophila Models, Patient-Derived Cell Lines, and HSALR Mice.Semantic proximity Read ↗

The hallmarks of myotonic dystrophy type 1 muscle dysfunctionSemantic proximity Read ↗

Small Molecules Which Improve Pathogenesis of Myotonic Dystrophy Type 1Semantic proximity Read ↗

Vorinostat Improves Myotonic Dystrophy Type 1 Splicing Abnormalities in DM1 Muscle Cell Lines and Skeletal Muscle from a DM1 Mouse ModelSemantic proximity Read ↗

Targeting deregulated AMPK/mTORC1 pathways improves muscle function in myotonic dystrophy type ISemantic proximity Read ↗

A Novel Class of FKBP12 Ligands Rescues Premature Aging Phenotypes Associated with Myotonic Dystrophy Type 1.Semantic proximity Read ↗

Targeting Myotonic Dystrophy Type 1 with Metformin.Semantic proximity Read ↗

Natural products, PGC-1 , and Duchenne muscular dystrophySemantic proximity Read ↗

AMPK is mitochondrial medicine for neuromuscular disordersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.